Bendectin and Birth Defects : : The Challenges of Mass Toxic Substances Litigation / / Michael D. Green.
Benedictin was prescribed to more than thirty-five million American women from its introduction in 1956 until 1983, when it was withdrawn from the market. The drug's manufacturer, Merrill Dow Pharmaceuticals, a major U.S. pharmaceutical firm, joined a list of other companies whose product liabi...
Saved in:
| Superior document: | Title is part of eBook package: De Gruyter University of Pennsylvania Press Package Archive 1898-1999 |
|---|---|
| VerfasserIn: | |
| Place / Publishing House: | Philadelphia : : University of Pennsylvania Press, , [2016] ©1996 |
| Year of Publication: | 2016 |
| Language: | English |
| Online Access: | |
| Physical Description: | 1 online resource (384 p.) |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Table of Contents:
- Frontmatter
- Contents
- Preface
- Acknowledgments
- Chapter 1. A Birth Defect Child Is Born
- Chapter 2. Locating Bendectin Within the Mass Toxic Landscape
- Chapter 3. The Science of Determining Toxic Causation
- Chapter 4. The Food and Drug Administration
- Chapter 5. The Wm. S. Merrell Company
- Chapter 6. A Mother's Quest
- Chapter 7. The Mekdeci Case
- Chapter 8. The Unraveling Of Mekdeci
- Chapter 9. The Proliferation of Bendectin Litigation
- Chapter 10. Litigating a Multidistrict Case
- Chapter 11. The Withdrawal of Bendectin
- Chapter 12. Forging a Mass Toxic Substances Trial
- Chapter 13. The Settlement and Unsettlement of MDL-486
- Chapter 14. The MDL-486 Trial
- Chapter 15. Aggregative Procedure in Mass Toxic Substances Litigation
- Chapter 16. The Third Phase of Bendectin Litigation: Oxendine, Richardson, and the Individual Trials
- Chapter 17. The Legacy of Bendectin for Toxic Causation Law
- Chapter 18. The Lessons and Non-Lessons of Bendectin Litigation
- Selected Bibliography
- Index